Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
348 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Closed (3)

Medical Condition

  • Show all (237)
  • Addiction (4)
  • Autoimmune Disorders (15)
  • Blood Disorders (26)
    • Amyloidosis (10)
    • (-) Anemia (1)
    • Sickle Cell Disease (1)
  • Bone & Muscle (1)
  • Cancer (4)
  • Child Development (1)
  • Developmental Disorders (1)
  • Endocrine & Metabolic Disease (2)
  • Hair and Skin Disorders (2)
  • Healthy Volunteers (8)
  • Heart Disease (1)
  • Liver Disease (1)
  • Lung Disease (2)
  • Meniere's Disease (1)
  • Neurological Disorders (112)
  • Obstetrics & Gynecology (3)
    • Pregnancy (1)
    • (-) Reproductive & Hormonal Disorders (2)
  • Pediatrics (6)
  • Psychiatric Disorders (47)
Displaying 1 - 3 of 3

Study of Rapamycin in Delaying the Start of Menopause

Condition: Obstetrics & Gynecology / Reproductive & Hormonal Disorders
Investigator: S. Zev Williams, MD, PhD
Status: Closed
Researchers at Columbia are looking at new treatments to help delay the start of menopause. This is a randomized trial where some women will receive medication and some will receive a placebo. The study will last approximately 12 weeks, followed by monthly follow-ups for 6 months. Participants will be compensated $1300 for compensation.
Read More

A study for Menopausal women using an investigational drug TX004-HR to reduce the frequency of hot flushes.

Condition: Obstetrics & Gynecology / Reproductive & Hormonal Disorders
Investigator: Rogerio Lobo, MD, FACOG
Status: Closed
The purpose of this study is to evaluate a new experimental (investigational) oral combination hormone drug product containing estradiol (a form of the estrogen) and progesterone (a female hormone that regulates the inner lining of the uterus called the endometrium) for postmenopausal women who have hot flushes. The estradiol and progesterone used in this…
Read More

A study for patients with Iron Refractory Iron-Deficiency Anemia (IRIDA) using study drug Triferic

Condition: Blood Disorders / Anemia
Investigator: Katherine Ender, MD
Status: Closed
The main purpose of the study is to find out whether Triferic, when taken by mouth (orally) with Shohls solution, is safe and effective for the treatment of Iron Refractory Iron-Deficiency Anemia (IRIDA). The study drug, ferric pyrophosphate citrate (FPC), is also called Triferic. It is an iron salt that has been approved by the Food and Drug Administration…
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science